Skip to main content
Top
Published in: Journal of Natural Medicines 3/2009

Open Access 01-07-2009 | Original Paper

Protective effect of the ethanol extract of Magnolia officinalis and 4-O-methylhonokiol on scopolamine-induced memory impairment and the inhibition of acetylcholinesterase activity

Authors: Yong Kyung Lee, Dong Yeon Yuk, Tae Il Kim, Young Heui Kim, Kyoung Tae Kim, Ki Ho Kim, Beom Jun Lee, Sang-Yoon Nam, Jin Tae Hong

Published in: Journal of Natural Medicines | Issue 3/2009

Login to get access

Abstract

Magnolol, honokiol, and obovatol are well-known bioactive constituents of the bark of Magnolia officinalis and have been used as traditional Chinese medicines for the treatment of neurosis, anxiety, and stroke. We recently isolated novel active compound (named 4-O-methylhonokiol) from the ethanol extract of Magnolia officinalis. The present study aimed to test two different doses of ethanol extracts of Magnolia officinalis (5 and 10 mg/kg/mouse, p.o., 1 week) and 4-O-methylhonokiol (0.75 and 1.5 mg/kg/mouse, p.o., 1 week) administered for 7 days on memory impairment induced by scopolamine (1 mg/kg body weight i.p.) in mice. Memory and learning were evaluated using the Morris water maze and the step-down avoidance test. Both the ethanol extract of Magnolia officinalis and 4-O-methylhonokiol prevented memory impairment induced by scopolamine in a dose-dependent manner. The ethanol extract of Magnolia officinalis and 4-O-methylhonokiol also dose-dependently attenuated the scopolamine-induced increase of acetylcholinesterase (AChE) activity in the cortex and hippocampus of mice, and inhibited AChE activity in vitro with IC50 (12 nM). This study, therefore, suggests that the ethanol extract of Magnolia officinalis and its major ingredient, 4-O-methylhonokiol, may be useful for the prevention of the development or progression of AD.
Literature
1.
go back to reference Abramov AY, Canevari L, Duchen MR (2003) Changes in intracellular calcium and glutathione in astrocytes as the primary mechanism of amyloid neurotoxicity. J Neurosci 15:5088–5095 Abramov AY, Canevari L, Duchen MR (2003) Changes in intracellular calcium and glutathione in astrocytes as the primary mechanism of amyloid neurotoxicity. J Neurosci 15:5088–5095
2.
go back to reference Butterfield DA (1997) Beta-amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer’s disease. Chem Res Toxicol 10:495–506PubMedCrossRef Butterfield DA (1997) Beta-amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer’s disease. Chem Res Toxicol 10:495–506PubMedCrossRef
3.
go back to reference Ho PI, Collins SC, Dhitavat S, Ortiz D, Ashline D, Rogers E, Shea TB (2001) Homocysteine potentiates beta-amyloid neurotoxicity: role of oxidative stress. J Neurochem 78:249–253PubMedCrossRef Ho PI, Collins SC, Dhitavat S, Ortiz D, Ashline D, Rogers E, Shea TB (2001) Homocysteine potentiates beta-amyloid neurotoxicity: role of oxidative stress. J Neurochem 78:249–253PubMedCrossRef
4.
go back to reference Parks JK, Smith TS, Trimmer PA, Bennett JP Jr, Parker WD Jr (2001) Neurotoxic Abeta peptides increase oxidative stress in vivo through NMDA-receptor and nitric-oxide-synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro. J Neurochem 76:1050–1056PubMedCrossRef Parks JK, Smith TS, Trimmer PA, Bennett JP Jr, Parker WD Jr (2001) Neurotoxic Abeta peptides increase oxidative stress in vivo through NMDA-receptor and nitric-oxide-synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro. J Neurochem 76:1050–1056PubMedCrossRef
5.
go back to reference Pappolla MA, Chyan YJ, Omar RA, Hsiao K, Perry G, Smith MA, Bozner P (1998) Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer’s disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am J Pathol 152:871–877PubMed Pappolla MA, Chyan YJ, Omar RA, Hsiao K, Perry G, Smith MA, Bozner P (1998) Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer’s disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am J Pathol 152:871–877PubMed
6.
go back to reference Namba T, Nolte CT, Jackrel J, Grob D (1971) Poisoning due to organophosphate insecticides. Acute and chronic manifestations. Am J Med 50:475–492PubMedCrossRef Namba T, Nolte CT, Jackrel J, Grob D (1971) Poisoning due to organophosphate insecticides. Acute and chronic manifestations. Am J Med 50:475–492PubMedCrossRef
7.
go back to reference Ellis JM (2005) Cholinesterase inhibitors in the treatment of dementia. J Am Osteopath Assoc 105:145–158PubMed Ellis JM (2005) Cholinesterase inhibitors in the treatment of dementia. J Am Osteopath Assoc 105:145–158PubMed
8.
go back to reference Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J (1992) A controlled trial of tacrine in Alzheimer’s disease. The Tacrine Study Group. JAMA 268:2523–2529PubMedCrossRef Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J (1992) A controlled trial of tacrine in Alzheimer’s disease. The Tacrine Study Group. JAMA 268:2523–2529PubMedCrossRef
9.
go back to reference Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI (1994) A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. The Tacrine Study Group. JAMA 271:985–991PubMedCrossRef Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI (1994) A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. The Tacrine Study Group. JAMA 271:985–991PubMedCrossRef
10.
go back to reference Lahiri DK, Farlow MR, Grieg NH, Sambamurti K (2002) Current drug targets for Alzheimer’s disease treatment. Drug Dev Res 56:267–281CrossRef Lahiri DK, Farlow MR, Grieg NH, Sambamurti K (2002) Current drug targets for Alzheimer’s disease treatment. Drug Dev Res 56:267–281CrossRef
11.
go back to reference Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT (1998) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology 50:136–145PubMed Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT (1998) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology 50:136–145PubMed
12.
go back to reference Hatip-Al-Khatib I, Egashira N, Mishima K, Iwasaki K, Iwasaki K, Kurauchi K, Inui K, Ikeda T, Fujiwara M (2004) Determination of the effectiveness of components of the herbal medicine Toki-Shakuyaku-San and fractions of Angelica acutiloba in improving the scopolamine-induced impairment of rat’s spatial cognition in eight-armed radial maze test. J Pharmacol Sci 96:33–41PubMedCrossRef Hatip-Al-Khatib I, Egashira N, Mishima K, Iwasaki K, Iwasaki K, Kurauchi K, Inui K, Ikeda T, Fujiwara M (2004) Determination of the effectiveness of components of the herbal medicine Toki-Shakuyaku-San and fractions of Angelica acutiloba in improving the scopolamine-induced impairment of rat’s spatial cognition in eight-armed radial maze test. J Pharmacol Sci 96:33–41PubMedCrossRef
13.
go back to reference Kang SY, Lee KY, Park MJ, Kim YC, Markelonis GJ, Oh TH, Kim YC (2003) Decursin from Angelica gigas mitigates amnesia induced by scopolamine in mice. Neurobiol Learn Mem 79:11–18PubMedCrossRef Kang SY, Lee KY, Park MJ, Kim YC, Markelonis GJ, Oh TH, Kim YC (2003) Decursin from Angelica gigas mitigates amnesia induced by scopolamine in mice. Neurobiol Learn Mem 79:11–18PubMedCrossRef
14.
go back to reference Kang SY, Lee KY, Koo KA, Yoon JS, Lim SW, Kim YC, Sung SH (2005) ESP-102, a standardized combined extract of Angelica gigas, Saururus chinensis and Schizandra chinensis, significantly improved scopolamine-induced memory impairment in mice. Life Sci 76:1691–1705PubMedCrossRef Kang SY, Lee KY, Koo KA, Yoon JS, Lim SW, Kim YC, Sung SH (2005) ESP-102, a standardized combined extract of Angelica gigas, Saururus chinensis and Schizandra chinensis, significantly improved scopolamine-induced memory impairment in mice. Life Sci 76:1691–1705PubMedCrossRef
15.
go back to reference Houghton PJ, Agbedahunsi JM, Adegbulugbe A (2004) Choline esterase inhibitory properties of alkaloids from two Nigerian Crinum species. Phytochemistry 65:2893–2896PubMedCrossRef Houghton PJ, Agbedahunsi JM, Adegbulugbe A (2004) Choline esterase inhibitory properties of alkaloids from two Nigerian Crinum species. Phytochemistry 65:2893–2896PubMedCrossRef
16.
go back to reference Yamada N, Hattori A, Hayashi T, Nishikawa T, Fukuda H, Fujino T (2004) Improvement of scopolamine-induced memory impairment by Z-ajoene in the water maze in mice. Pharmacol Biochem Behav 78:787–791PubMedCrossRef Yamada N, Hattori A, Hayashi T, Nishikawa T, Fukuda H, Fujino T (2004) Improvement of scopolamine-induced memory impairment by Z-ajoene in the water maze in mice. Pharmacol Biochem Behav 78:787–791PubMedCrossRef
17.
go back to reference Yan JJ, Kim DH, Moon YS, Jung JS, Ahn EM, Baek NI, Song DK (2004) Protection against beta-amyloid peptide-induced memory impairment with long-term administration of extract of Angelica gigas or decursinol in mice. Prog Neuropsychopharmacol Biol Psychiatry 28:25–30PubMedCrossRef Yan JJ, Kim DH, Moon YS, Jung JS, Ahn EM, Baek NI, Song DK (2004) Protection against beta-amyloid peptide-induced memory impairment with long-term administration of extract of Angelica gigas or decursinol in mice. Prog Neuropsychopharmacol Biol Psychiatry 28:25–30PubMedCrossRef
18.
go back to reference Yu MS, Leung SK, Lai SW, Che CM, Zee SY, So KF, Yuen WH, Chang RC (2005) Neuroprotective effects of anti-aging oriental medicine Lycium barbarum against beta-amyloid peptide neurotoxicity. Exp Gerontol 40:716–727PubMedCrossRef Yu MS, Leung SK, Lai SW, Che CM, Zee SY, So KF, Yuen WH, Chang RC (2005) Neuroprotective effects of anti-aging oriental medicine Lycium barbarum against beta-amyloid peptide neurotoxicity. Exp Gerontol 40:716–727PubMedCrossRef
19.
go back to reference Song WZ, Cui JF, Zhang GD (1989) Studies on the medicinal plants of Magnoliaceae tu-hou-po of Manglietia. Yao Xue Xue Bao 24:295–299PubMed Song WZ, Cui JF, Zhang GD (1989) Studies on the medicinal plants of Magnoliaceae tu-hou-po of Manglietia. Yao Xue Xue Bao 24:295–299PubMed
20.
go back to reference Tsai TH, Westly J, Lee TF, Chen CF, Wang LCH (1995) Effects of honokiol and magnolol on acetylcholine release from rat hippocampal slices. Planta Med 61:477–479PubMedCrossRef Tsai TH, Westly J, Lee TF, Chen CF, Wang LCH (1995) Effects of honokiol and magnolol on acetylcholine release from rat hippocampal slices. Planta Med 61:477–479PubMedCrossRef
21.
go back to reference Yamazaki R, Sugatani J, Fujii I, Kuroyanagi M, Umehara K, Ueno A, Suzuki Y, Miwa M (1994) Development of a novel method for determination of acetyl-CoA:1-alkyl-sn-glycero-3-phosphocholine acetyltransferase activity and its application to screening for acetyltransferase inhibitors. Inhibition by magnolol and honokiol from Magnoliae cortex. Biochem Pharmacol 47:995–1006PubMedCrossRef Yamazaki R, Sugatani J, Fujii I, Kuroyanagi M, Umehara K, Ueno A, Suzuki Y, Miwa M (1994) Development of a novel method for determination of acetyl-CoA:1-alkyl-sn-glycero-3-phosphocholine acetyltransferase activity and its application to screening for acetyltransferase inhibitors. Inhibition by magnolol and honokiol from Magnoliae cortex. Biochem Pharmacol 47:995–1006PubMedCrossRef
22.
go back to reference Fukuyama Y, Otoshi Y, Miyoshi K, Nakamura K, Kodama M, Nagasawa M, Hasegawa T, Okazaki H, Sugawara M (1992) Neurotrophic sesquiterpene-neolignans from Magnolia obovata: structure and neurotrophic activity. Tetrahedron 48:377–392CrossRef Fukuyama Y, Otoshi Y, Miyoshi K, Nakamura K, Kodama M, Nagasawa M, Hasegawa T, Okazaki H, Sugawara M (1992) Neurotrophic sesquiterpene-neolignans from Magnolia obovata: structure and neurotrophic activity. Tetrahedron 48:377–392CrossRef
23.
go back to reference Seo JJ, Lee SH, Lee YS, Kwon BM, Ma Y, Hwang BY, Hong JT, Oh KW (2007) Anxiolytic-like effects of obovatol isolated from Magnolia obovata: involvement of GABA/benzodiazepine receptors complex. Prog Neuropsychopharmacol Biol Psychiatry 31:1363–1369PubMedCrossRef Seo JJ, Lee SH, Lee YS, Kwon BM, Ma Y, Hwang BY, Hong JT, Oh KW (2007) Anxiolytic-like effects of obovatol isolated from Magnolia obovata: involvement of GABA/benzodiazepine receptors complex. Prog Neuropsychopharmacol Biol Psychiatry 31:1363–1369PubMedCrossRef
24.
go back to reference Ogren SO (1985) Evidence for a role of brain serotonergic neurotransmission in avoidance learning. Acta Physiol Scand Suppl 544:1–71PubMed Ogren SO (1985) Evidence for a role of brain serotonergic neurotransmission in avoidance learning. Acta Physiol Scand Suppl 544:1–71PubMed
25.
go back to reference Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11:47–60PubMedCrossRef Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11:47–60PubMedCrossRef
26.
go back to reference Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88–95PubMedCrossRef Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88–95PubMedCrossRef
27.
go back to reference Checler F (1995) Processing of the beta-amyloid precursor protein and its regulation in Alzheimer’s disease. J Neurochem 65:1431–1444PubMedCrossRef Checler F (1995) Processing of the beta-amyloid precursor protein and its regulation in Alzheimer’s disease. J Neurochem 65:1431–1444PubMedCrossRef
28.
29.
go back to reference Hardy JA, Higgins GA (1992) Alzheimer’s disease: the amyloid cascade hypothesis. Science 256:184–185PubMedCrossRef Hardy JA, Higgins GA (1992) Alzheimer’s disease: the amyloid cascade hypothesis. Science 256:184–185PubMedCrossRef
30.
go back to reference Hwang DY, Chae KR, Kang TS, Hwang JH, Lim CH, Kang HK, Goo JS, Lee MR, Lim HJ, Min SH, Cho JY, Hong JT, Song CW, Paik SG, Cho JS, Kim YK (2002) Alterations in behavior, amyloid beta-42, caspase-3, and Cox-2 in mutant PS2 transgenic mouse model of Alzheimer’s disease. FASEB J 16:805–813PubMedCrossRef Hwang DY, Chae KR, Kang TS, Hwang JH, Lim CH, Kang HK, Goo JS, Lee MR, Lim HJ, Min SH, Cho JY, Hong JT, Song CW, Paik SG, Cho JS, Kim YK (2002) Alterations in behavior, amyloid beta-42, caspase-3, and Cox-2 in mutant PS2 transgenic mouse model of Alzheimer’s disease. FASEB J 16:805–813PubMedCrossRef
31.
go back to reference Barnes CA, Danysz W, Parsons CG (1996) Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur J Neurosci 8:565–571PubMedCrossRef Barnes CA, Danysz W, Parsons CG (1996) Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur J Neurosci 8:565–571PubMedCrossRef
32.
go back to reference Hou YC, Chao PD, Chen SY (2000) Honokiol and magnolol increased hippocampal acetylcholine release in freely-moving rats. Am J Chin Med 28:379–384PubMedCrossRef Hou YC, Chao PD, Chen SY (2000) Honokiol and magnolol increased hippocampal acetylcholine release in freely-moving rats. Am J Chin Med 28:379–384PubMedCrossRef
33.
go back to reference Lal H, Kumar B, Forster MJ (1988) Enhancement of learning and memory in mice by a benzodiazepine antagonist. FASEB J 2:2707–2711PubMed Lal H, Kumar B, Forster MJ (1988) Enhancement of learning and memory in mice by a benzodiazepine antagonist. FASEB J 2:2707–2711PubMed
34.
go back to reference Preston GC, Ward C, Lines CR, Poppleton P, Haigh JR, Traub M (1989) Scopolamine and benzodiazepine models of dementia: cross-reversals by Ro 15-1788 and physostigmine. Psychopharmacology (Berl) 98:487–494CrossRef Preston GC, Ward C, Lines CR, Poppleton P, Haigh JR, Traub M (1989) Scopolamine and benzodiazepine models of dementia: cross-reversals by Ro 15-1788 and physostigmine. Psychopharmacology (Berl) 98:487–494CrossRef
35.
go back to reference Smythe JW, Murphy D, Costall B (1996) Benzodiazepine receptor stimulation blocks scopolamine-induced learning impairments in a water maze task. Brain Res Bull 41:299–304PubMedCrossRef Smythe JW, Murphy D, Costall B (1996) Benzodiazepine receptor stimulation blocks scopolamine-induced learning impairments in a water maze task. Brain Res Bull 41:299–304PubMedCrossRef
36.
go back to reference Vazquez J, Baghdoyan HA (2003) Muscarinic and GABAA receptors modulate acetylcholine release in feline basal forebrain. Eur J Neurosci 17:249–259PubMedCrossRef Vazquez J, Baghdoyan HA (2003) Muscarinic and GABAA receptors modulate acetylcholine release in feline basal forebrain. Eur J Neurosci 17:249–259PubMedCrossRef
Metadata
Title
Protective effect of the ethanol extract of Magnolia officinalis and 4-O-methylhonokiol on scopolamine-induced memory impairment and the inhibition of acetylcholinesterase activity
Authors
Yong Kyung Lee
Dong Yeon Yuk
Tae Il Kim
Young Heui Kim
Kyoung Tae Kim
Ki Ho Kim
Beom Jun Lee
Sang-Yoon Nam
Jin Tae Hong
Publication date
01-07-2009
Publisher
Springer Japan
Published in
Journal of Natural Medicines / Issue 3/2009
Print ISSN: 1340-3443
Electronic ISSN: 1861-0293
DOI
https://doi.org/10.1007/s11418-009-0330-z

Other articles of this Issue 3/2009

Journal of Natural Medicines 3/2009 Go to the issue